Mirtazapine Instant Eg (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine, and by antagonising postsynaptic 5‑HT2, 5‑HT3 and H1 receptors. This dual action enhances serotonergic and noradrenergic neurotransmission while providing antihistaminic effects, contributing to its antidepressant and sedative properties.

The appropriate dose of Mirtazapine Instant Eg is determined by the prescribing clinician based on the individual patient's condition, response, and tolerability. Dosage adjustments are made according to clinical judgment and patient-specific factors.

Safety data for mirtazapine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its combined noradrenergic and specific serotonergic activity and strong antihistaminic effect. It is often chosen for patients who need additional sedation or appetite stimulation, whereas SSRIs may have a more activating profile.

Mirtazapine Instant Eg should be stored at room temperature, below 25 °C, in its original packaging to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

The medication is taken orally, usually once daily in the evening, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include the potential for suicidal thoughts or behavior, especially during early treatment, agranulocytosis or severe neutropenia, and rare severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely for any sudden changes in mood or signs of infection.

Mirtazapine is contraindicated in patients who have taken a monoamine oxidase inhibitor within the past 14 days, or in individuals with known hypersensitivity to mirtazapine or any of its excipients. Caution is also advised for patients with severe hepatic impairment.